单次HDR近距离治疗作为低中危前列腺癌单一疗法:两项临床试验(含与不含MRI引导追加照射)的结果
两项II期临床试验比较单次19 Gy HDR单药治疗低中危前列腺癌时,加或不加MRI引导的前列腺内优势病灶(DIL)追加照射至至少23 Gy的结局。两组5年累计生化失败率分别为32.6%和31.3%(p=0.9),追加照射未改善局部控制,且失败率不可接受。作者建议单次HDR单药治疗仅限临床试验。
要点
- 单次19 Gy HDR单药治疗5年生化失败率约三成,不可接受。
- MRI引导DIL追加至至少23 Gy未改善局部控制,但安全耐受。
- 单次HDR单药治疗应仅限临床试验,不应常规提供。
核心结论
- MRI引导的局灶追加照射安全且耐受良好,但未改善19 Gy单次HDR单药治疗后的局部控制,且控制率不可接受。
- 单次HDR单药治疗前列腺癌不应在临床试验之外提供。
研究设计与样本
- 两项II期临床试验比较:Trial1单次19 Gy HDR全前列腺植入,Trial2加MRI引导DIL追加至至少23 Gy。
- Trial1纳入87例,中位随访62个月;Trial2纳入60例,中位随访50个月;患者为低或中危前列腺癌,不允许ADT。
主要发现
- 两组5年累计生化失败率分别为32.6%和31.3%(p=0.9)。
- 77.5%的失败为活检证实的局部失败,均接受了局部挽救治疗。
- 追加DIL未与更差毒性或生活质量相关。
- 基线PSA和Gleason评分与生化失败相关,但无剂量学参数是生化失败的显著预测因素。
关键数值与推荐
- 生化失败定义为nadir+2。
- Trial1单次HDR剂量19 Gy;Trial2追加MRI引导DIL剂量至少23 Gy。
- 毒性按CTCAEv4.0评估,生活质量按EPIC收集。
临床怎么用
- 单次HDR单药治疗不应作为低中危前列腺癌的常规治疗选择。
- 考虑单次HDR单药治疗时应仅限临床试验框架内。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Single-fraction HDR monotherapy for the treatment of localized prostate cancer is appealing, but published outcomes are discouraging. An approach to improve local control is MRI-guided focal dose-escalation to the dominant intraprostatic lesion (DIL). Here we report a comparison of outcomes from two phase II clinical trials with and without a focal boost. METHODS: Patients had low or intermediate-risk disease. Patients in Trial1 received a single 19 Gy HDR implant to the whole prostate. Trial2 incorporated an additional MRI-guided focal DIL boost to at least 23 Gy. ADT was not allowed. Toxicities (CTCAEv4.0) and quality of life (EPIC) were collected. Biochemical failure (BF) was defined as nadir +2. Univariate and multivariate logistic regression analysis was conducted to search for predictors of BF. RESULTS: Trial1 had 87 patients with a median follow-up of 62 months, while Trial2 had 60 patients with a median follow-up of 50 months. The five-year cumulative BF rate was 32.6% and 31.3%, respectively (p = 0.9). 77.5% of failures were biopsy-confirmed local failures, all of which underwent local salvage therapy. The addition of a DIL boost was not associated with worse toxicity or QOL. Baseline PSA and Gleason score correlated with BF, but none of the dosimetric parameters was a significant predictor of BF. CONCLUSIONS: MRI-guided focal boost was safe and well tolerated, but did not improve local control after 19 Gy single-fraction HDR monotherapy, and the control rates were unacceptable. Single-fraction HDR monotherapy for prostate cancer should not be offered outside of clinical trials.
引用
- Alayed Y, Loblaw A, McGuffin M, et al. Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost. Radiother Oncol. 2020. PMID: 32918971. doi:10.1016/j.radonc.2020.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。